Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategy
- 18 March 2004
- Vol. 22 (23-24) , 3205-3213
- https://doi.org/10.1016/j.vaccine.2003.11.060
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (15019072, AI47089, 14570215)
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology (15C-5)
This publication has 17 references indexed in Scilit:
- Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trialsVaccine, 2002
- P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functionsThe EMBO Journal, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- A Region ofPlasmodium falciparumAntigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking AntibodiesInfection and Immunity, 2000
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000
- DNA vaccination strategies against infectious diseasesInternational Journal for Parasitology, 1999
- Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking AntibodiesInfection and Immunity, 1999
- Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine CandidatesMolecular Medicine, 1998
- Antimalarial drugs and the mosquito transmission of PlasmodiumInternational Journal for Parasitology, 1997
- A vaccine candidate from the sexual stage of human malaria that contains EGF-like domainsNature, 1988